Dr. Sulaiman Al Habib Medical Services Group (4013) is listed on Tadawul of the Saudi Exchange (Tadawul) under sector Health Care Equipment & Svc. Financial data sourced from CMA-mandated XBRL filings via Sahm Screener (sahmscreener.com).

For fiscal year 2025, Dr. Sulaiman Al Habib Medical Services Group reported revenue of SAR 13.71B, net profit of SAR 2.40B, and earnings per share of SAR 6.86. Total assets stood at SAR 23.20B with total equity of SAR 7.90B and total liabilities of SAR 14.78B.

Operating cash flow for 2025 was SAR 3.40B, representing a cash conversion ratio of 1.42 relative to net profit. Free cash flow was SAR 431M.

Earnings quality analysis by Sahm Screener: Of every SAR 1.00 in reported net profit for 2025, SAR 1.42 arrived as operating cash. This indicates Exceptional quality earnings based on the cash conversion ratio of 1.42.

Revenue growth from 2024 to 2025: +22.4%. Net profit growth over the same period: +3.7%. 3-year revenue CAGR: 35.1%. 3-year net profit CAGR: 13.3%.

Key financial ratios for 2025: Return on Equity 30.4%, Return on Assets 10.3%, Net Margin 17.5%, Debt to Equity 1.87.

In 2024, Dr. Sulaiman Al Habib Medical Services Group reported revenue of SAR 11.20B and net profit of SAR 2.32B, compared to SAR 13.71B and SAR 2.40B respectively in 2025.